Ondansetron Reduce Vomiting Associated With Ketamine PSA
Information source: University of Colorado, Denver
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Conscious Sedation
Intervention: Ondansetron (Drug)
Sponsored by: University of Colorado, Denver
Official(s) and/or principal investigator(s):
Joe E Wathen, MD, Principal Investigator, Affiliation: University of Colorado Health Science Center
Ondansetron, a commonly used anti-vomiting medication, may reduce the occurrence of vomiting
associated with ketamine during procedural sedation in the pediatric emergency department.
Official title: Does Ondansetron Reduce the Incidence of Vomiting When Used in Conjunction With Ketamine During Procedural Sedation in the Pediatric Emergency Department
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Primary outcome: incidence of vomiting
Length of ED stay
Satisfaction with Sedation
Minimum age: 1 Year.
Maximum age: 21 Years.
- age 1-21 years, ASA I or II, fracture of dislocation reduction
- age < 1 year, ASA III or IV, hypertension, glaucoma, acute globe injury, increased
intracranial pressure or central nervous system mass lesion, major psychiatric
disorder, porphyria, previous adverse reaction to ketamine or ondansetron, parent,
guardian or patient unwilling to provide informed consent.
Locations and Contacts
The Childrens Hospital, Denver, Colorado 80218, United States
Starting date: December 2002
Last updated: May 9, 2013